Obstetric Cholestasis (ICP) in India: Itching, UDCA & Delivery

• ICP is severe third-trimester itching, classically on the palms and soles, worst at night, with no rash to explain it.
• It is confirmed by a blood test for total serum bile acids; a level above 10 micromoles per litre with typical itching diagnoses ICP.
• Severity is graded by the peak bile acid level: mild (10-39), moderate (40-99) and severe (100 or more) — this single number drives every decision.
• UDCA (Udiliv, Ursofalk, generics) is the first-line medicine; it eases the itching and improves liver tests but does not by itself prevent stillbirth.
• Planned delivery is the main way to protect the baby — around 37-39 weeks for mild ICP, 36-37 for moderate, and 34-36 for severe.
• Itching settles within days of delivery and liver tests return to normal in 4-6 weeks; but ICP comes back in 60-70% of future pregnancies.

ICP is a liver condition unique to pregnancy. Normally, bile flows from your liver cells into your small intestine. In ICP that flow slows, and bile acids that should be cleared instead build up in your bloodstream. It is overwhelmingly a third-trimester condition — most women notice it after 28 weeks and the great majority after 30 weeks — although a small number present earlier in the second trimester.

The cause is a mix of things working together. There is a clear genetic tendency involving bile-acid transporter genes (which is why ICP runs in families and tends to recur), a hormonal trigger from the high oestrogen and progesterone of late pregnancy, and environmental contributors such as selenium deficiency. This combination is thought to explain why ICP is far commoner in South Asian women than in European or North American ones.

The standout symptom is itching, and the pattern is so typical that an experienced obstetrician often suspects ICP from the description alone. It is severe — many women say it is the worst itch of their lives — and it is worst on the palms of the hands and the soles of the feet, dramatically worse at night, and there is no rash to explain it. If a true rash is present (anything beyond your own scratch marks), the diagnosis is usually something else, such as the pregnancy rash PUPPP, eczema or scabies. Some women in more severe cases also notice mild jaundice (yellow eyes or skin), dark urine, pale stools, tiredness or discomfort under the right ribs, but itching dominates.

ICP affects around 4-7% of pregnancies in India — roughly four times the European and North American rates, among the highest reported anywhere. Because it is this common here, the threshold for testing should be low: any pregnant woman with persistent third-trimester itching, especially on the palms and soles and worse at night, deserves a bile acid test without delay.

ICP is diagnosed by combining the typical symptoms with a blood test, and both halves matter. The clinical half is severe, persistent itching in the third trimester (sometimes late second), worst on the palms and soles, worst at night, with no rash. Scratch marks are expected, but any primary rash — raised bumps, blisters, redness in a set pattern — points to another diagnosis and is worth a closer look. Our guide to vaginal and vulval itching covers some of the itch conditions that are sometimes confused with ICP.

The laboratory half is a measurement of total serum bile acids. A value above 10 micromoles per litre, alongside typical itching, confirms ICP (FOGSI and RCOG 2022 guidelines use this threshold). The sample no longer needs to be taken fasting — current guidelines accept a non-fasting sample. The test is widely available at Dr Lal PathLabs, Metropolis, SRL, Thyrocare and Apollo Diagnostics for roughly Rs 500-1,200, with results in one to two days. Your doctor will usually order it alongside the routine antenatal bloods covered in our first-visit pregnancy blood tests guide.

Your doctor will also order liver function tests (often showing raised ALT and AST, sometimes raised bilirubin), a complete blood count, and an ultrasound of the liver and gallbladder. Other conditions need to be ruled out: gallstones and bile-duct obstruction (the ultrasound usually clarifies these), viral hepatitis (hepatitis A, B, C and especially E, which is dangerous in pregnancy in India), autoimmune liver disease, drug-induced liver injury, and — in late pregnancy with abnormal liver tests — HELLP syndrome or acute fatty liver, which usually carry other clues such as high blood pressure or clotting problems. Once ICP is confirmed and these are excluded, the focus shifts to grading severity and planning delivery.

Severity in ICP is based on the peak total bile acid level, and this single number is the most important one in the whole condition — it drives how closely you are monitored, the medicine, and above all the timing of delivery. The FOGSI and RCOG 2022 guidelines use three bands: mild ICP is 10-39 micromoles per litre, moderate is 40-99, and severe is 100 or more.

These cut-offs exist because the risk of harm to the baby rises in a clear stepwise way as bile acids climb. The key evidence is a large 2019 meta-analysis published in The Lancet, which pooled many ICP studies and showed that the stillbirth risk stays close to the background pregnancy risk below 40 micromoles per litre, rises modestly between 40 and 99, and rises sharply at 100 and above. The same pattern holds for early (preterm) birth, meconium-stained fluid and neonatal-unit admission. That is why early delivery is justified for severe ICP, slightly-early delivery for moderate, and near-term delivery for mild.

A few practical points. First, the level can change, so a single reading is not the whole story — the peak across pregnancy is what counts, and bile acids are rechecked at intervals because a woman who starts mild can progress. Second, how bad the itching feels does not reliably track the bile acid level: some women itch terribly with only mild elevation, others barely itch with severe disease, so symptoms never replace the lab value for grading. Third, very early-onset ICP (before 30 weeks) tends to be more severe and to recur more strongly. Fourth, ICP can travel with other complications such as gestational diabetes and Preeclampsia in Pregnancy: Diagnosis and Care in India, so screening for these continues alongside ICP care.

The reason ICP is actively managed rather than simply watched is that raised maternal bile acids cross the placenta and create real risks for the baby, rising sharply with the bile acid level. There are three main concerns: early (preterm) birth, meconium-stained fluid with possible fetal distress, and stillbirth.

Preterm birth in ICP is partly spontaneous — raised bile acids seem to make the uterus more excitable — and partly planned, when doctors deliver early to reduce the stillbirth risk. The overall preterm rate in ICP is around 20-30%, versus roughly 10% in pregnancies generally, but most of this is late preterm (34-36 weeks), and these babies usually do well with little or no special care. If your doctor anticipates a delivery before 34-35 weeks, you will be offered a course of antenatal corticosteroids to mature the baby's lungs. For warning signs of labour starting on its own, see our guide to preterm labour and what to do.

Meconium-stained amniotic fluid is also commoner in ICP — around 20-30% of pregnancies, versus 10-15% generally — reflecting irritation of the baby's gut by bile acids. Meconium is not itself harmful but signals stress and slightly raises the chance of meconium aspiration at birth, especially in a long or difficult labour. The standard response is continuous fetal monitoring in labour, a low threshold for caesarean if distress appears, and a paediatric team ready at delivery.

Stillbirth is the most serious risk and the reason for close watching. Averaged across all severities it is around 1-2%, but that average hides a stepwise pattern: the risk is close to the background level (roughly 2-3 per 1,000) below 40 micromoles per litre, rises to around 4-5 per 1,000 between 40 and 99, and climbs steeply to about 3% (30 per 1,000) at 100 or above. The stillbirth tends to happen late and often without warning that routine monitoring can catch — which is exactly why timing the delivery, rather than waiting for monitoring to flag a problem, is the cornerstone of prevention. Severe ICP left to run to full term carries a stillbirth risk of around 10%, the level that justifies delivery at 34-36 weeks.

Ursodeoxycholic acid — UDCA, sold in India as Udiliv, Udcell, Ursofalk and several generics — is the first-line medicine and is started by most Indian obstetricians as soon as ICP is confirmed. UDCA is itself a naturally occurring bile acid; it competes with the more harmful bile acids and shifts the balance of the bile acid pool towards a less toxic mix. The usual dose is 10-15 mg per kg of body weight per day, commonly 300 mg three times daily for an average-sized woman (900 mg a day), sometimes higher in more severe disease. It is taken until delivery and stopped straight afterwards.

What UDCA does and does not do has been clarified by the PITCH trial, a large UK randomised study published in 2019. It clearly reduces the itching (a real quality-of-life win, given that the itch is the dominant complaint) and clearly improves the liver biochemistry. However, it did not show a statistically significant improvement in the main combined outcome for the baby (stillbirth, preterm birth or neonatal-unit admission). Later analyses suggest a modest benefit for the baby, mainly in severe ICP, but the honest headline is this: UDCA is given mainly for maternal symptom relief and better biochemistry. The reduction in stillbirth risk comes chiefly from timed delivery, not from UDCA alone.

UDCA is generally very well tolerated. The commonest side effects are mild, brief nausea or loose stools, and a few women find the itch worsens for a few days before easing. There are no known harmful effects on the baby. It costs roughly Rs 500-1,500 a month depending on brand and dose and is available at most pharmacies on prescription. Other measures are sometimes added — antihistamines such as cetirizine or chlorpheniramine for the itch, menthol-based cooling creams, and, in resistant severe cases under specialist care, rifampicin or S-adenosylmethionine — but UDCA remains the mainstay and is enough for most women. After delivery it is simply stopped, with no need to taper.

Timing of delivery is the single most important decision in ICP and the main lever for preventing stillbirth, because the risk climbs in the final weeks. Earlier delivery removes that risk in exchange for the small, manageable risk of a late-preterm birth. The FOGSI and RCOG 2022 guidelines, which Indian obstetricians broadly follow, set the timing by the peak bile acid level.

For mild ICP (peak 10-39 micromoles per litre), planned delivery at 37-39 weeks is standard. This is essentially routine term timing and adds almost no neonatal risk, while removing the small extra stillbirth risk of going past 39 weeks with ICP — see what is happening at this stage in our week 37 pregnancy guide.

For moderate ICP (peak 40-99), planned delivery at 36-37 weeks is standard. This is late preterm, and most babies need little or no special care at this gestation, while the reduction in stillbirth risk is meaningful. For severe ICP (peak 100 or more), planned delivery at 34-36 weeks is standard, sometimes after a course of antenatal corticosteroids if delivery is planned before 34-35 weeks. At 34-36 weeks most babies do well, though a few need a short neonatal-unit stay for feeding support or transient breathing trouble — worth knowing in advance.

The method of delivery in ICP is usually induction of labour aiming for a vaginal birth, not a planned caesarean. ICP on its own is not a reason for caesarean, and vaginal birth is preferred when otherwise feasible. The caesarean rate is somewhat higher than in unaffected pregnancies because of more fetal distress in labour, but a vaginal trial is the starting point unless there is another reason for caesarean (a previous caesarean, malpresentation, placenta previa, or distress before induction). Your doctor will discuss timing and method at an antenatal visit, often around 32-34 weeks, so you and your family can prepare. For how the cervix changes during induction, see our guide to cervical effacement and dilation.

Active monitoring is the second cornerstone of ICP care, alongside timed delivery, and it intensifies with severity and as pregnancy advances.

Maternal bile acid monitoring comes first. Bile acids are rechecked weekly from diagnosis until delivery, because the level can rise and a woman who starts mild may move into the moderate or severe band, bringing the delivery date forward. Liver function tests are usually done at the same time. In clearly mild, stable ICP some doctors check fortnightly, reserving weekly checks for moderate or severe disease — a reasonable, pragmatic approach.

Fetal monitoring is where most surveillance focuses. The non-stress test (NST) records the baby's heart rate for 20-30 minutes looking for reassuring accelerations; it is the workhorse of ICP monitoring, typically done twice weekly from 32 weeks, and costs around Rs 500-1,000 per test. The biophysical profile (BPP) adds an ultrasound look at the baby's breathing, movements, tone and fluid for a score out of 10, and is typically done weekly in moderate and severe ICP at around Rs 1,500-3,000. Our guide to fetal monitoring (NST, BPP, CTG) explains what each test checks and what the scores mean.

Daily kick counts done by you at home are the third element — simple, free and important. The usual advice is to count 10 distinct movements within two hours at a regular time (often after a meal, when the baby is liveliest), and to contact your doctor or go to the labour ward immediately if you do not reach 10, or if the usual pattern clearly drops. Honesty matters here: NST and BPP have limits in ICP — stillbirth in severe disease can occur acutely between normal tests, which is precisely why monitoring complements timed delivery rather than replacing it. For a wider picture of the third trimester, see our week-by-week pregnancy guide.

Induction of labour is the standard way ICP pregnancies are delivered at the planned week, following the usual Indian induction protocols with a few ICP-specific touches. It starts with cervical ripening if the cervix is unfavourable (a Bishop score below 6 — long, firm and barely dilated). Options include a Foley balloon catheter (mechanical, increasingly preferred in India for being effective, inexpensive and clean on safety), prostaglandin E2 (dinoprostone gel or pessary), and low-dose misoprostol (25 micrograms every 4-6 hours). All three are pregnancy-safe; the choice depends on the hospital and your doctor. Our induction of labour in India guide covers these methods in detail.

Once the cervix is favourable (Bishop score above 6, often after one or two doses of ripening agent or an overnight Foley), an oxytocin drip is started and slowly increased until contractions come every 2-3 minutes, lasting 45-60 seconds. Continuous electronic fetal monitoring is standard throughout an ICP induction (rather than the intermittent monitoring acceptable in low-risk labour), because the risk of fetal distress is higher and early detection allows quicker action. Your waters may be broken (amniotomy) at a suitable point to speed things along.

Pain relief is the same as for any induction. An epidural is the most effective option and is genuinely safe in ICP — the routine pre-epidural platelet check covers any theoretical concern, and ICP usually does not affect platelets. Gas-and-air (nitrous oxide) is available in many private Indian hospitals, intravenous opioids such as tramadol are an option (less effective than an epidural), and non-drug methods — position changes, a labour ball, breathing techniques — are encouraged. A caesarean is done if there is fetal distress not relieved by simple measures, if labour fails to progress despite an adequate trial, or for a fresh obstetric reason. The caesarean rate in ICP inductions is around 20-30% — higher than uncomplicated labour, but still leaving most women with a vaginal birth. For more on epidural choices and costs, see our epidural in Indian labour guide.

Recovery from ICP is fast and reassuring. The itching that has dominated and exhausted you usually starts to ease within a day or two of delivery and is essentially gone within a week. Your liver biochemistry — bile acids and liver tests — returns to normal over 4-6 weeks, occasionally a little longer after severe disease. UDCA is stopped immediately at delivery, with no taper. A follow-up bile acid and liver test at 6-8 weeks (around Rs 500-1,200) is reasonable to confirm full recovery, especially after severe ICP, and fits neatly into the routine six-week postnatal visit.

Breastfeeding is safe and encouraged, just as in any pregnancy. UDCA passes into breast milk only in tiny amounts and is considered compatible if it is ever continued. The baby needs no special routine tests beyond normal newborn care, unless born preterm or after meconium-stained fluid, in which case the usual preterm or post-meconium care applies. Vitamin K is given to all newborns in India and is especially worthwhile after ICP, given the slightly higher clotting risk.

The most important thing to know is that ICP comes back. Around 60-70% of women who had ICP in one pregnancy will have it again in the next, often earlier and sometimes more severe. This matters for family planning and for managing the next pregnancy: your doctor will test bile acids early at the first hint of itching, plan closer monitoring from the second trimester, and again expect a planned delivery. On contraception, oestrogen-containing methods (the combined pill, vaginal ring or patch) can occasionally trigger cholestasis-like symptoms in women with a history of ICP and are best discussed with your doctor; progesterone-only options are usually safer choices. Our guides to the pill, mini-pill and what actually suits you and to copper IUD versus Mirena can help you weigh the options. Copper IUD and barrier methods are also safe.

The cost of ICP care in India varies widely between the government system, smaller private hospitals and the large private chains, and planning for it is part of the conversation. Obstetrician consultations at chains such as Apollo Cradle, Cloudnine, Manipal, Fortis and Max run roughly Rs 500-2,500 a visit, with the most senior consultants at the top end. A hepatologist review, sometimes added for severe or unusual ICP, is around Rs 1,500-4,000. In the government system, antenatal care through PMSMA (Pradhan Mantri Surakshit Matritva Abhiyan) on the 9th of each month and at the district hospital antenatal clinic is free, and gastroenterology referral in district and medical college hospitals is free or nominal.

For investigations: bile acids cost around Rs 500-1,200 per test at the major labs, a liver function panel Rs 400-1,000, a liver-and-obstetric ultrasound Rs 800-2,000, an NST Rs 500-1,000, and a BPP Rs 1,500-3,000. In the public system these are free at district hospital and medical college level for women in the antenatal programme. UDCA costs roughly Rs 500-1,500 a month; the Janani Shishu Suraksha Karyakram (JSSK) covers essential medicines free at public facilities, though UDCA is not always on every facility's standard list, so it is worth asking your doctor.

Induced delivery in private hospitals ranges from around Rs 50,000 at smaller facilities for a vaginal birth to roughly Rs 1-2 lakh for a caesarean at the large chains, varying by city. In the government system, delivery is essentially free under JSSK, which covers normal and caesarean delivery, newborn care, medicines, consumables and transport at public facilities for both rural and urban women. Other helpful schemes include Janani Suraksha Yojana (JSY), which gives a cash incentive for institutional delivery to women below the poverty line in low-performing states, and Pradhan Mantri Matru Vandana Yojana (PMMVY), which provides Rs 5,000 for the first live birth; ESI and CGHS cover organised-sector workers and government employees, and most private health insurance covers ICP care and delivery. An ABHA digital health ID (under the Ayushman Bharat Digital Mission) keeps your antenatal records portable across facilities — handy for ICP, where lab tests and visits stack up. The honest summary: ICP is well covered in both government and private systems, and cost should not be a barrier to good care.

ICP needs prompt medical attention, and once diagnosed it is managed actively. Contact your obstetrician or go to the labour ward without delay if any of the following apply.

Most of these are about the itch and the baby's movements rather than the itch alone — both matter.

• RCOG Green-top Guideline No. 43: Intrahepatic Cholestasis of Pregnancy (2022)
• Ovadia C, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers (meta-analysis). The Lancet, 201931877-4/fulltext)
• Chappell LC, et al. Ursodeoxycholic acid versus placebo in women with ICP (PITCH trial). The Lancet, 201931270-X/fulltext)
• NHS: Itching and intrahepatic cholestasis of pregnancy (obstetric cholestasis)
• Ministry of Health and Family Welfare (India): Janani Shishu Suraksha Karyakram (JSSK)